News | October 25, 2013

Cardiovascular Research Foundation Appoints Jack Lewin as CEO

Healthcare executive takes helm at interventional cardiology foundation

October 25, 2013 — The Cardiovascular Research Foundation (CRF) announced the appointment of John (Jack) Lewin, M.D., as the foundation’s president and CEO. Lewin was also appointed to CRF’s board of directors. CRF believes Lewin brings a unique blend of leadership and management skills to the organization. He succeeds William Himmelsbach, who retired in late 2012. Colette Gardner, CRF board member, served as president and co-chair of the Executive Leadership Council in the interim.
 
“Since its inception in 1990, CRF has played a major role in the great progress that has been made in interventional cardiology, and in realizing dramatic improvements in the lives of countless patients by establishing the safe use of new technologies and therapies for heart disease,” said Lewin. “I look forward to working with CRF’s iconic physicians who are so passionate about advancing the field. The combination of preclinical research, clinical trials and excellence in education under one roof gives the foundation a distinctive ability to generate important research questions, test and refine groundbreaking new therapies, and ensure that these therapies are available to patients at the earliest possible opportunity.”
 
“Jack Lewin’s distinguished background and remarkably innovative tenure as CEO of the American College of Cardiology make him an exceptional individual for this position,” said Eric Woldenberg, chairman, CRF board of directors and senior partner, Pryor Cashman LLP.  “His proven leadership skills, along with his expertise in both the business and clinical aspects of health care, will enable him to help us strengthen and expand our role in the development of new technologies and therapies that will benefit people with heart disease worldwide.” 
 
Lewin served as CEO of the American College of Cardiology (ACC) from 2006 to April 2012. Prior to the ACC, Lewin was CEO of the California Medical Association for eight years. Previously, he was Hawaii’s director of health from 1986-1994, overseeing 6,500 employees, 12 hospitals and a $1 billion budget. Before that, as a commissioned officer in the U.S. Public Health Service, Lewin was the founder and first director of the Navajo Nation Department of Health, serving the needs of America’s largest Indian tribe. He currently serves as the voluntary chairman of the board for the National Coalition on Health Care. In 2011, he was named as one of Modern Healthcare’s 100 most influential people in Healthcare.
 
For more information: www.crf.org
 

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init